2014

Cancer Vaccine Partnering Terms and Agreements

NEW YORK, May 16, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Vaccine Partnering Terms and Agreements

http://www.reportlinker.com/p01181005/Cancer-Vaccine-Partnering-Terms-and-Agreements.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering dealsDisclosed headlines, upfronts, milestones and royalties by stage of developmentCancer vaccine partnering contract documentsTop cancer vaccine deals by value

The Cancer Vaccine Partnering Agreements report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 500 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of cancer vaccine dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in cancer vaccine dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.It also provides the number of deals entered by top 50 big pharma and most active dealmakers in cancer vaccine partnering.

Chapter 3 provides a review of the leading cancer vaccine deals since 2007. Deals are listed by headline value, signed by big pharma and big biotech. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive and detailed review of cancer vaccine partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. The report also includes adjuvant deals and alliances.

The report also includes numerous tables and figures that illustrate the trends and activities in cancer vaccine partnering and dealmaking since 2007. This report comes with an additional appendix containing entire list of cancer vaccine dealmakers by Company A-Z, deal type and stage of development.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of cancer vaccine technologies and products.

Report scope

Cancer Vaccine Partnering Agreements is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Cancer Vaccine Partnering Agreements includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2007

Analysis of cancer vaccine deal structure

Access to headline, upfront, milestone and royalty data

Access to over 200 cancer vaccine deal records

The leading cancer vaccine deals by value since 2007

Includes adjuvant and drug delivery deals and alliances since 2007

In Cancer Vaccine Partnering Agreements, the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Cancer Vaccine Partnering Agreements report provides comprehensive access to available deals and contract documents for over 500 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?What is actually granted by the agreement to the partner company?What exclusivity is granted?What is the payment structure for the deal?How aresales and payments audited?What is the deal term?How are the key terms of the agreement defined?How are IPRs handled and owned?Who is responsible for commercialization?Who is responsible for development, supply, and manufacture?How is confidentiality and publication managed?How are disputes to be resolved?Under what conditions can the deal be terminated?What happens when there is a change of ownership?What sublicensing and subcontracting provisions have been agreed?Which boilerplate clauses does the company insist upon?Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?Which jurisdiction does the company insist upon for agreement law?

Cancer Vaccine Partnering Agreements provides the reader with the following key benefits: In-depth understanding of cancer vaccine deal trends since 2007

Access to headline, upfront, milestone and royalty data

Acces to the structure of cancer vaccine agreements with numerous real life case studies

Comprehensive access to over 150 actual cancer vaccine deals entered into by the world's biopharma companies

Insight into the terms included in a cancer vaccine agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

TABLE OF CONTENTS Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in cancer vaccine dealmaking

2.1. Introduction

2.2. Cancer vaccine partnering over the years

2.3. Bigpharma cancer vaccine dealmaking activity

2.4. Most active in cancer vaccine partnering

2.5. Cancer vaccine partnering by deal type

2.6. Cancer vaccine partnering by stage of development

2.7. Cancer vaccine partnering by cancer indication

2.8. Disclosed deal terms for cancer vaccine partnering

2.8.1 Cancer vaccine partnering headline values

2.8.2 Cancer vaccine deal upfront payments

2.8.3 Cancer vaccine deal milestone payments

2.8.4 Cancer vaccine royalty rates

2.9. The anatomy of cancer vaccine partnering

2.9. The anatomy of a cancer vaccine deal

2.9.a. Case study 1: Stemline Therapeutics, University of Pittsburgh- March 30 2012

2.9.b. Case study 2: University of Pennsylvania- VGX Pharmaceuticals: April 24, 2007

Chapter 3 – Leading cancer vaccine deals

3.1. Introduction

3.2. Top cancer vaccine deals by value

Chapter 4 – Cancer vaccine dealmaking directory

4.1. Introduction

4.2. Company A-Z

3M

Adamis Pharmaceuticals

Adjuvantix

AdnaGen

Aduro BioTech

Advaxis

Affitech

Agenus Bio

Aldevron

Alexis Biotech

Alligator Bioscience

Alnylam Pharmaceuticals

AnGes MG

Antigen Express

Antigenics

Argos Therapeutics

Ariad Pharmaceuticals

Arizona State University

Astrimmune

Australian Centre for Vaccine Development

Avantogen Oncology

AVAX Technologies

Averion

Bavarian Nordic

Bayer Innovation

Baylor College

Baylor College of Medicine

Baylor Research Institute

Beijing Genomics Institute (BGI)

Bellicum Pharmaceuticals

Berlex

Beth Israel Deaconess Medical Center

Binex

BinnoPharm

Bio-Matrix Scientific

BioAlliance Pharma

Biomira

BioSante Pharmaceuticals

BioVest

BioWa

BN ImmunoTherapeutics

Brigham Young University

Bristol-Myers Squibb

Broadvector

BT Pharma

Cadila Pharmaceuticals

Cancer Research and Prevention Institute of Texas

Cancer Research Institute

Cancer Research Technology

Cancer Research UK

Cancer Research Wales

Cancer Treatment Centers of America

Cardiff University

Catherex

Cedars-Sinai Medical Center

Cell Genesys

Celldex Therapeutics

Celltrion

CG Therapeutics

Champions Oncology

ChemRar High-Tech Center

City of Hope

Clinipace Worldwide

Cobra Biologics

Colby Pharmaceuticals

CSIRO

CSL

CureLab Oncology

CureVac

Cyto Pulse Sciences

Cytos

Daiichi Sankyo

Dalton Pharma Services

Dana-Farber Cancer Institute

Delta-Vir

Dendreon

Department of Defense

Diosynth

Dynavax Technologies

EMD Serono

Encorium Group

Entest BioMedical

Favrille

Federal Ministry of Education and Research (BMBF)

Formatech

Fraunhofer Institute for Cell Therapy and Immunology

Fred Hutchinson Cancer Research Center

G-Con

Galena Biopharma

Genentech

Generex Biotechnology

Genetic Immunity

GenoLac

Genomic Expression

German Cancer Research Center

German Ministry for Education and Research

GlaxoSmithKline

Government of United Kingdom

Gradalis

Hawaii Biotechnology

HemaCare

HemispheRx Biopharma

Henderson Morley

IBio

Ichor Medical Systems

IDIS Pharma

Immatics Biotechnologies

Immune Design

ImmuneRegen BioSciences

ImmunoCellular Therapeutics

Immunomedics

Immunotope

Immunovaccine

ImmunoVaccine Technologies

Immunovo

ImmuRx

Inovio Biomedical

Inovio Pharmaceuticals

Institut Pasteur

IRX Therapeutics

ISSI-Strategy

Jaiva Technologies

Jantibody Therapeutics

Japan Vaccine

Jennerex

Johns Hopkins University

JSC Binnopharm

Juvaris BioTherapeutics

KAEL-GemVax

Karolinska Institute

KellBenx

Kirin Pharma

Kyowa Hakko Kirin

Lipoxen

London Genetics

Ludwig Institute for Cancer Research

MabVax Therapeutics

Mary Crowley Cancer Research Center

Maxcyte

Mayo Clinic

MD Anderson Cancer Center

MDxHealth

Medarex

MediGene

MedImmune

Memorial Sloan Kettering Cancer Center

Merck & Co

Merck KGaA

Merck Serono

Merix Bioscience

Methodist Hospital Research Institute

MorphoSys

Mount Sinai School of Medicine

Natco Pharmaceuticals

National Cancer Institute

National Cancer Research Center

National Institute of Allergy and Infectious Diseases

National Institutes of Health

National Research Council Canada

NeoStem

NewVac

Northwest Biotherapeutics

Norwegian Research Council

Novartis

Novavax

Numoda

NYU Langone Medical Center

Ohio State University

Omnimmune

OncoMethylome

OncoPep

Oncotherapy Science

Oncothyreon

Oncovir

Ono Pharmaceutical

Onyvax

Opsona Therapeutics

Oxford BioMedica

Oxford Immunotec

PDS Biotechnology

Pepscan Therapeutics

Pevion

Pfenex

Pfizer

Pharmexa

Pharmsynthez

Pique Therapeutics

Pro-Cure Therapeutics

Progenitor Cell Therapy

Prostate Cancer Foundation (PCF)

PsiOxus Therapeutics

Public Health Service

Qiagen

Radboud University Nijmegen Medical Centre

Radient Pharmaceuticals

Roche

RXi Pharmaceuticals

Saint Savas Cancer Hospital

Sanofi-Aventis

SBI Biotech

Scancell

Scripps Research Institute

Serum Institute of India

SOTIO

Stellar Biotechnologies

Stellar Pharmaceuticals

Stemline Therapeutics

Symphony Dynamo

Systems Biology Worldwide

Takeda Pharmaceutical

TapImmune

Tasly Pharmaceuticals

Technomark Life Sciences

Teva Pharmaceuticals

The Regents of the University of California

Therinject

ToleRx

Torrey Pines Institute for Molecular Studies

Transgene

UK Government

UK Technology Strategy Board

University of Chicago

University of Connecticut

University of Copenhagen

University of Florida

University of Liege

University of North Carolina

University of Pennsylvania

University of Pennsylvania School of Veterinary Medicine

University of Pittsburgh

University of Queensland

University of Washington

Uppsala University

Vaccibody

Vaccinogen

Vaxil BioTherapeutics

Vaximm

VGX Pharmaceuticals

ViroMed

Vivalis

VLST Corporation

Wistar Institute

Wittycell

Wuxi Apptec Laboratory Services

Xencor

4.3. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

Regulatory

4.4. By deal type

Asset purchase

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Manufacturing

Marketing

Material transfer

Option

Research

Settlement

Sub-license

Supply

Technology transfer

Termination

Warranty

4.5. By oncology therapy area

Oncology

4.6. By related technology

Adjuvant

Vaccines

Chapter 5 –Partnering resource center

5.1. Online partnering

5.2. Partnering events

5.3. Further reading on dealmaking

Appendices

Appendix 1 – Deal type definitions

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Therapy Reports

Order Form – Reports

Table of Figures Figure 1: Cancer vaccine partnering since 2007

Figure 2: Bigpharma – top 50 – cancer vaccine deals 2007 to 2013

Figure 3: Big pharma cancer vaccine deal frequency – 2007 to 2013

Figure 4: Active cancer vaccine dealmaking activity– 2007 to 2013

Figure 5: Cancer vaccine partnering by deal type since 2007

Figure 6: Cancer vaccine partnering by stage of development since 2007

Figure 7: Vaccine partnering by oncology target since 2007

Figure 8: Cancer vaccine deals with a headline value – by stage of development

Figure 9: Cancer vaccine deal headline value – median value by stage of development

Figure 10: Cancer vaccine deals with upfront payment values – by stage of development

Figure 11: Cancer vaccine deal upfront payment value – median value by stage of development

Figure 12: Cancer vaccine deals with milestone payment – by stage of development

Figure 13: Cancer vaccine deals with royalty rates-by stage of development

Figure 14: Components of the typical cancer vaccine deal structure

Figure 15: Top cancer vaccine deals by value since 2007

Figure 16: Online partnering resources

Figure 17: Forthcoming partnering events

Figure 18: Deal type definitions

To order this report:Biopharmaceutical Industry: Cancer Vaccine Partnering Terms and Agreements

Contact Clare: clare@reportlinker.com

US:(339) 368 6001

Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.